dc.contributor.author | Ooms, M | |
dc.contributor.author | Strom, A | |
dc.contributor.author | Strassburger, K | |
dc.contributor.author | Menart, B | |
dc.contributor.author | Leslie, RD | |
dc.contributor.author | Schloot, NC | |
dc.contributor.author | Action LADA Study Group# | |
dc.date.accessioned | 2021-01-12T16:23:18Z | |
dc.date.available | 2020-12-14 | |
dc.date.available | 2021-01-12T16:23:18Z | |
dc.date.issued | 2020-12-23 | |
dc.identifier.citation | Ooms, M., Strom, A., Strassburger, K., Menart, B., Leslie, R.D., Schloot, N.C. and (2021), Increased spontaneous CCL2 (MCP‐1) and CCL5 (RANTES) secretion in vitro in LADA compared to type 1 diabetes and type 2 diabetes: Action LADA 14. Diabetes Metab Res Rev. Accepted Author Manuscript. https://doi.org/10.1002/dmrr.3431 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/69649 | |
dc.description.abstract | AIMS: Immune-mediated type 1 diabetes (T1D) in adulthood and latent autoimmune diabetes in adults (LADA) share similar pathological mechanisms but differ clinically in disease progression. The aim of this study was to acquire insights into spontaneous and stimulated chemokine secretion of immune cells in different diabetes types. MATERIALS AND METHODS: We investigated in vitro spontaneous, mitogen (PI) and antigen (HSP60, p277, pGAD, pIA2) stimulated chemokine secretion of leucocytes from patients with T1D (n=32), LADA (n=22), type 2 diabetes (T2D) (n=49), and glucose-tolerant individuals (n=13). Chemokine concentration in supernatants was measured for CCL2 (MCP-1), CXCL10 (IP10) and CCL5 (RANTES) using a multiplex bead array assay. RESULTS: Spontaneous secretion of CCL2 and CCL5 were higher in LADA compared to T1D and T2D (all p<0.05) while CXCL10 was similar in the groups. Mitogen stimulated secretion of CCL2 in LADA was lower compared to T1D and T2D (all p<0.05) while CXCL10 and CCL5 were similar in all groups. Upon stimulation with pIA2 the secretion of CCL2 in LADA was lower compared to T2D (p<0.05). Spontaneous CXCL10 secretion in LADA was positively associated with BMI (r2 =0.35; p=0.0035) and C-peptide (r2 =0.30; p=0.009). CONCLUSIONS: In conclusion, chemokine secretion is altered between different diabetes types. Increased spontaneous secretion of CCL2 and CCL5 and decreased secretion of CCL2, upon stimulation with PI and pIA2, in LADA compared to T1D and T2D could reflect altered immune responsiveness in LADA patients in association with their slower clinical progression compared to insulin dependence. This article is protected by copyright. All rights reserved. | en_US |
dc.language | eng | |
dc.relation.ispartof | Diabetes/metabolism research and reviews | |
dc.rights | "This is the peer reviewed version of the following article: Ooms, M., Strom, A., Strassburger, K., Menart, B., Leslie, R.D., Schloot, N.C. and (2021), Increased spontaneous CCL2 (MCP‐1) and CCL5 (RANTES) secretion in vitro in LADA compared to type 1 diabetes and type 2 diabetes: Action LADA 14. Diabetes Metab Res Rev. Accepted Author Manuscript. https://doi.org/10.1002/dmrr.3431 This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions." | |
dc.subject | CCL2 | en_US |
dc.subject | CCL5 | en_US |
dc.subject | CXCL10 | en_US |
dc.subject | latent autoimmune diabetes in adults | en_US |
dc.subject | type 1 diabetes | en_US |
dc.subject | type 2 diabetes | en_US |
dc.title | Increased spontaneous CCL2 (MCP-1) and CCL5 (RANTES) secretion in vitro in LADA compared to type 1 diabetes and type 2 diabetes: Action LADA 14. | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1002/dmrr.3431 | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33369072 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
dcterms.dateAccepted | 2020-12-14 | |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |
qmul.funder | A BLUEPRINT of Haematopoietic Epigenomes::European Commission | en_US |
qmul.funder | A BLUEPRINT of Haematopoietic Epigenomes::European Commission | en_US |
qmul.funder | A BLUEPRINT of Haematopoietic Epigenomes::European Commission | en_US |